Multigene panel testing surfaces clinically actionable findings unrelated to the reason testing was ordered — ACMG secondary findings policy, patient consent, and care coordination
Modern clinical genetic testing rarely sequences a single gene in isolation. A patient with suspected hypertrophic cardiomyopathy is typically tested with a "cardiomyopathy panel" spanning 30–150+ genes, or increasingly with exome or genome sequencing filtered down to a virtual panel. The clinical indication defines only which gene the ordering physician cares about — the sequencing technology itself does not respect that boundary, and every other gene captured by the assay is, in principle, readable.
A hybridization-capture or amplicon-based cardiomyopathy panel is built around a set of genes with strong evidence for the phenotype in question — for hypertrophic cardiomyopathy, this centers on sarcomeric genes like MYH7, MYBPC3, TNNT2, TNNI3, and TPM1. Laboratories bundle these into a single reportable panel for efficiency and cost, but the underlying chemistry (targeted capture, amplicon PCR, or off-target exome reads) frequently produces usable sequence data for genes far outside the cardiac indication.
When testing moves to exome or genome sequencing — increasingly common because it is cheaper per-base than custom panel design and allows re-analysis as knowledge grows — the laboratory generates a complete readout of essentially every protein-coding gene in the genome, then bioinformatically filters to a "virtual panel" matching the ordering indication. The rest of the data still exists in the file. This is the technical origin of the incidental/secondary finding: the assay does not know, or care, why the test was ordered.
These three terms are often used loosely but have precise meanings in clinical genetics:
• Primary finding: a variant in the gene(s) directly relevant to the clinical indication that prompted testing (e.g., MYH7 for suspected cardiomyopathy).
• Incidental finding: any unexpected finding discovered as a byproduct of testing, unrelated to the indication, that the laboratory was not specifically looking for.
• Secondary finding: a specific policy term (coined by ACMG) for a curated subset of incidental findings that laboratories are recommended to actively, deliberately analyze and report — regardless of the original indication — because the associated conditions are highly actionable (a preventive intervention, surveillance protocol, or treatment exists).
Every secondary finding is a type of incidental finding, but not every incidental finding qualifies as a secondary finding. A variant of uncertain significance in an obscure gene with no established management pathway is incidental but is not part of the ACMG secondary findings framework.
Because broad sequencing all but guarantees that some unrelated, medically significant variant will eventually turn up in someone's data, most laboratories and genetics guidelines require the opt-in/opt-out decision to happen before the test is run — not after a finding is already sitting in a report. This pre-test consent conversation is where genetic counseling does its most consequential work.
Pre-test genetic counseling walks the patient through a structured choice, typically framed as:
• Opt-in: "If we find a pathogenic variant in one of the ~80+ ACMG secondary findings genes, unrelated to why you're being tested today, we will actively look for it and report it to you and your ordering provider."
• Opt-out: "We will only analyze and report variants in the gene(s) relevant to your cardiac indication. We will not examine or disclose findings in unrelated genes, even if the data technically contains them."
This is a deliberate, documented decision — not a default buried in fine print. Laboratories differ in exact mechanics (some offer granular opt-in by disease category, such as cancer-only or cardiac-only secondary findings), but the ACMG recommendation for clinical exome/genome sequencing is a binary pre-test choice offered to every patient, revisited at each new testing episode.
Deciding after a finding already exists creates an impossible position: the laboratory or ordering clinician would need to disclose the mere existence of an unrelated finding to obtain consent to disclose its content — which is itself a disclosure. Pre-test consent avoids this paradox entirely by establishing the reporting rule in advance, so that when analysis is performed, the laboratory already knows whether the secondary findings pipeline should even run.
Studies of patient preference consistently show that most patients, when adequately counseled, choose to receive secondary findings — reasoning that actionable information about cancer or cardiac arrhythmia risk in themselves or their relatives is valuable even when unrelated to the original complaint. A meaningful minority opt out, most often citing concerns about insurance discrimination, psychological burden, or simply wanting to keep the test focused on the original question.
Bioinformatic analysis proceeds in two conceptually separate tracks that happen to run over the same underlying sequence data: the primary indication track evaluates the gene(s) relevant to the ordering diagnosis, while — only if the patient opted in — a secondary findings track independently screens the ACMG SF gene list for reportable pathogenic variants, entirely irrespective of the cardiac question that started the whole process.
Once raw sequence reads are aligned and variants called, the bioinformatics pipeline splits into separate interpretive tracks. The primary track applies ACMG/AMP variant classification criteria specifically to genes on the cardiomyopathy indication list, searching for a variant that explains the patient's clinical presentation. The secondary findings track — gated entirely by the patient's opt-in status recorded at the pre-test consent step — independently interrogates the fixed ACMG SF gene panel for pathogenic or likely pathogenic variants, using the same rigorous classification standard but with no connection whatsoever to the cardiac phenotype.
In the scenario animated here, the primary track successfully identifies a pathogenic MYH7 variant explaining the hypertrophic cardiomyopathy. Independently, the secondary track flags a pathogenic BRCA1 variant — a gene with no relationship to cardiac muscle function, discovered purely because it happened to be captured by the sequencing assay and happened to sit on the ACMG SF list the patient consented to have screened.
A narrow, disease-specific panel of 20-40 genes has a comparatively small chance of also containing a pathogenic variant in an unrelated ACMG SF gene, simply because so few genes are being examined. Comprehensive panels covering 150+ genes raise that probability. Exome sequencing (all ~20,000 protein-coding genes) and genome sequencing raise it further still, because the secondary findings track can be run against literally every SF gene without needing extra assay design — the data is already there.
This is a direct, quantifiable trade-off of broader testing: greater diagnostic yield for the primary indication (and the ability to reflex to a wider search if the initial panel is negative) comes bundled with a materially higher chance of surfacing a clinically significant, unrelated finding that then has to be managed, disclosed, and acted upon.
Not every unexpected variant gets reported back, even if opted in. The American College of Medical Genetics and Genomics (ACMG) maintains a specific, periodically-updated list of genes for which secondary findings should be actively sought and reported — currently comprising roughly 80+ genes. A finding only becomes a reportable "secondary finding" if the gene appears on this curated list; everything else, however interesting, is filtered out.
The ACMG SF list is deliberately narrow. Inclusion criteria emphasize genes where:
• A pathogenic variant carries high penetrance for a serious, life-altering condition. • A validated preventive intervention, surveillance protocol, or treatment meaningfully changes the outcome if the finding is known in advance (e.g., enhanced breast/ovarian cancer surveillance and risk-reducing surgery for BRCA1/2; implantable defibrillator consideration and family screening for arrhythmia genes like KCNQ1/KCNH2/RYR2; avoidance of triggering anesthetic agents for malignant hyperthermia risk genes RYR1/CACNA1S). • The evidence for pathogenicity and clinical actionability is robust enough to justify disclosing a finding the patient did not ask about.
The list spans hereditary cancer syndromes (BRCA1/2, Lynch syndrome genes MLH1/MSH2/MSH6/PMS2, TP53/Li-Fraumeni, APC/MUTYH-associated polyposis), cardiovascular conditions (cardiomyopathy and arrhythmia genes, familial hypercholesterolemia genes LDLR/APOB/PCSK9), and a smaller set of other actionable conditions such as malignant hyperthermia susceptibility.
ACMG has revised the secondary findings list multiple times since its original 2013 publication (v1.0, 56 genes), expanding and occasionally removing genes as evidence about penetrance, actionability, and clinical utility accumulates. A gene can be added because new data demonstrates strong actionability, or removed if follow-up evidence shows the original inclusion was not well supported. Laboratories are expected to apply the version current at the time of analysis, and some offer re-analysis of archived exome/genome data against newer list versions years later.
This versioning matters clinically: a patient sequenced several years ago under an older list version may not have been screened for genes added since, which is one argument favored by some clinicians for periodic re-contact or re-analysis, balanced against the practical burden of maintaining long-term contact with every sequenced patient.
A pathogenic variant in a gene NOT on the ACMG SF list is not disclosed as a secondary finding, however striking it might look to the analyst — the list exists precisely to draw a bright, evidence-based, consistently-applied line around what gets actively reported, rather than leaving disclosure to individual judgment call.
A cardiologist who ordered a cardiomyopathy panel is not the right clinician to manage a BRCA1 finding. Once results are finalized, the primary finding and the secondary finding must be routed through two different, appropriately-matched care pathways — and the secondary finding typically triggers a conversation about cascade testing for relatives who may share the same inherited risk.
The primary MYH7 finding closes the diagnostic loop the cardiologist opened: it confirms the genetic cause of the patient's hypertrophic cardiomyopathy, informs prognosis, and guides family screening within cardiology. The incidental BRCA1 finding, by contrast, has essentially nothing to do with the cardiology visit that triggered testing — it needs to be routed to a genetic counselor and, typically, a breast/ovarian cancer risk specialist or oncology genetics clinic, who can translate the result into a concrete surveillance and risk-reduction plan (enhanced imaging, consideration of risk-reducing surgery, chemoprevention).
This handoff is the most operationally fragile step in the entire process. The laboratory report may reach the ordering cardiologist, who has neither the training nor the clinical relationship to manage a hereditary cancer syndrome — so an explicit referral pathway, not just a mailed report, is required to actually connect the patient to the right specialist.
A pathogenic BRCA1 variant is inherited in an autosomal dominant pattern: each first-degree relative (parent, sibling, child) of the patient has roughly a 50% chance of carrying the same variant. Once a secondary finding is confirmed, genetic counseling extends beyond the original patient to discuss cascade testing — systematically offering targeted, low-cost single-variant testing to at-risk relatives, who can then pursue their own surveillance or risk-reducing decisions without needing a full panel or exome themselves.
Cascade testing is widely regarded as one of the highest-value activities in clinical genetics: it converts one incidental finding into risk-reducing opportunities for an entire family, but it depends entirely on the original patient being connected to a genetic counselor who can facilitate family communication and testing logistics — underscoring why care coordination, not just laboratory accuracy, determines whether a secondary finding actually improves outcomes.
The clinical value of the ACMG secondary findings framework is only realized if the disclosure pipeline actually connects the patient to a clinician equipped to act on the finding — an accurate BRCA1 result that never reaches oncology genetics delivers none of its intended benefit.